Clinical trial
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell…
NCT00090896 · Jonsson Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00090896 |
|---|---|
| Title | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery |
| Official title | A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination With MART-1 Peptide-Pulsed Dendritic Cells In Patients With Advanced Melanoma |
| Lead sponsor | Jonsson Comprehensive Cancer Center, Other |
| Collaborators | Pfizer Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Melanoma (Skin) |
| Intervention type | Biological |
| Interventions | maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody |
| Enrollment | 18 |
| Start date | Apr 1, 2004 |
| Primary completion | Jul 1, 2008 |
| Completion | Oct 1, 2009 |
| First posted | Sep 8, 2004 |
| Last update posted | Aug 3, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: